Log in

NASDAQ:PRTA - Prothena Stock Price, Forecast & News

$13.05
+0.13 (+1.01 %)
(As of 02/16/2020 01:58 PM ET)
Add
Today's Range
$12.71
Now: $13.05
$13.25
50-Day Range
$12.17
MA: $14.12
$16.00
52-Week Range
$6.71
Now: $13.05
$17.63
Volume109,804 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:PRTA
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees59
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.


Prothena (NASDAQ:PRTA) Frequently Asked Questions

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena's earnings last quarter?

Prothena Co. PLC (NASDAQ:PRTA) released its quarterly earnings results on Wednesday, February, 12th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.65) by $0.11. The biotechnology company had revenue of $0.26 million for the quarter, compared to analysts' expectations of $0.20 million. View Prothena's Earnings History.

When is Prothena's next earnings date?

Prothena is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Prothena.

What price target have analysts set for PRTA?

4 equities research analysts have issued 12-month target prices for Prothena's shares. Their forecasts range from $9.00 to $19.00. On average, they expect Prothena's stock price to reach $13.94 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price. View Analyst Price Targets for Prothena.

What is the consensus analysts' recommendation for Prothena?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Prothena.

Has Prothena been receiving favorable news coverage?

Headlines about PRTA stock have trended neutral recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Prothena earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Prothena.

What other stocks do shareholders of Prothena own?

Who are Prothena's key executives?

Prothena's management team includes the folowing people:
  • Mr. Gene G. Kinney, Pres, CEO & Director (Age 50)
  • Mr. Tran B. Nguyen, CFO & COO (Age 45)
  • Mr. Arthur W. Homan, Chief Legal Officer & Company Sec. (Age 60)
  • Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 56)
  • Dr. Wagner M. Zago, Chief Scientific Officer (Age 46)

Who are Prothena's major shareholders?

Prothena's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (8.34%), State Street Corp (2.60%), Goldman Sachs Group Inc. (1.18%), Pinnacle Associates Ltd. (1.00%), Bank of New York Mellon Corp (0.84%) and Point72 Asset Management L.P. (0.81%). View Institutional Ownership Trends for Prothena.

Which institutional investors are selling Prothena stock?

PRTA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Oxford Asset Management LLP, Platinum Investment Management Ltd., FMR LLC, Rafferty Asset Management LLC, UBS Group AG, Citigroup Inc. and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Prothena.

Which institutional investors are buying Prothena stock?

PRTA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Pinnacle Associates Ltd., Goldman Sachs Group Inc., Acadian Asset Management LLC, Ikarian Capital LLC, Russell Investments Group Ltd., Driehaus Capital Management LLC and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Prothena.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $13.05.


MarketBeat Community Rating for Prothena (NASDAQ PRTA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  515 (Vote Outperform)
Underperform Votes:  398 (Vote Underperform)
Total Votes:  913
MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe PRTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: What is Green Investing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel